Home Cart Sign in  
Chemical Structure| 67979-25-3 Chemical Structure| 67979-25-3

Structure of Aurantio-obtusin
CAS No.: 67979-25-3

Chemical Structure| 67979-25-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Nyarko, Mavis Sersah ; Danquah, Cynthia Amaning ; Antwi, Aaron Opoku ; Emikpe, Benjamin Obukowho ; Osafo, Newman ;

Abstract: Introduction: is a trihydroxyanthraquinone found in the seeds of Cassia tora and Cassia obtusifolia. Its neuroprotective, anti-inflammatory, anti-allergic, and potential has been documented in multiple studies. While previous reports mention its potential as an antiasthma agent, its effects on allergen‐induced airway inflammation have not been explored. Method: Our study reports on the mechanisms by which exerts its effects on underlying inflammation in experimentally‐induced allergic asthma. The effect of pretreatment on molecular and histological changes in guinea pig lungs when challenged with aerosolized ovalbumin was assessed. Results: Our results showed that significantly reduced ovalbumin (OVA)‐induced increase in serum OVA-specific immunoglobulin E (OVA‐sIgE) and intercellular adhesion molecule (ICAM)‐1. Aurantio‐obtusin further suppressed inflammatory cytokine expression (IL‐8, TNF‐α, IL‐6 and thymic stromal lymphopoietin) as well as malondialdehyde, a product of oxidative stress in bronchial lavage. The histopathological assessment showed a reduced transit of inflammatory cells and reduced deposition of collagen in the lungs of aurantio-obtusin-treated guinea pigs. Conclusion: Overall, the data suggests that mitigated ovalbumin‐induced airway inflammation by impeding the production of OVAsIgE and suppressing levels of key pro‐inflammatory cytokines. Our findings suggest that has potential benefits in the management of allergic airway inflammation in type 2 asthma.

Keywords: airway inflammation ; Allergy ; asthma ; ; intercellular adhesion molecule-1 ; plant-derived compound

Purchased from AmBeed:

Nyarko, Mavis Sersah ; Danquah, Cynthia Amaning ; Antwi, Aaron Opoku ;

Abstract: Allergic rhinitis (AR) is a growing global health concern. Despite being non-fatal, it has a detrimental effect on people′s quality of life and poses a significant economic burden. In this study, we aimed to evaluate the anti-allergic effects of against ovalbumin-induced murine model of allergic rhinitis. was administered to rats orally after sensitization to ovalbumin. Results of the study suggested that causes a significant reduction in nose rubs and sneeze as compared to the vehicle-treated disease control group. The treated group showed a dose-dependent significant reduction in serum TNF-α, IL-4, and IL-6 levels as well as levels in the nasal mucosa. Addnl., it decreased neutrophil and eosinophil numbers in blood of AR rats′. In the nasal tissues of the vehicle-treated rats that were subjected to an OVA challenge, the histol. of the nasal mucosa of AR rats revealed aberrant histol. changes. A variety of histol. abnormalities, including vascular congestion in the nasal mucosa, substantial inflammatory cell infiltration, and obvious alveolar wall edema were present. In the rats treated with , these characteristics were reversed. Collectively, the findings suggests that could be used to enhance current AR treatment approaches.

Keywords: Allergic rhinitis ; Aurantio-obtusin

Purchased from AmBeed:

Alternative Products

Product Details of Aurantio-obtusin

CAS No. :67979-25-3
Formula : C17H14O7
M.W : 330.29
SMILES Code : O=C1C2=C(C=C(C)C(O)=C2OC)C(C3=CC(O)=C(OC)C(O)=C13)=O
MDL No. :MFCD13194886
InChI Key :RNXZPKOEJUFJON-UHFFFAOYSA-N
Pubchem ID :155011

Safety of Aurantio-obtusin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
primary mature BAT adipocytes 15 μM 5 days AO significantly increased the activities of mitochondrial complexes I and IV and decreased ATP levels, suggesting that AO promotes energy expenditure by activating UCP1-mediated mitochondrial respiration uncoupling. Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840
Primary BAT adipocytes 15 μM 24 h To study the effect of AO on oxidative stress and mitochondrial function in primary BAT adipocytes, AO reduced oxidative stress and inhibited mPTP opening. Chin Med. 2025 Mar 25;20(1):41
AML12 cells 15 μM 24 h To investigate the effect of AO on inflammation in AML12 cells, AO reduced inflammation in AML12 cells by inhibiting mtDNA release from BAT cells. Chin Med. 2025 Mar 25;20(1):41
HepG2 cells 10-600 µM 48 h To evaluate the inhibitory effect of AO on liver cancer cell activity, the results showed that AO significantly inhibited the proliferation of SK-Hep1 and HepG2 cells. Int J Oncol. 2024 Oct;65(4):92
HepG2 cells 25 μM 3 and 5 h AO effectively promoted autophagy flux in HepG2 cells, as evidenced by a sustained increase in the number of red fluorescent puncta (autolysosomes). Front Pharmacol. 2022 Jan 11;12:826628
Mouse primary hepatocytes (MPHs) 12.5, 25, 50 μM 24 h AO significantly alleviated OAPA-induced lipid accumulation in hepatocytes, dose-dependently reduced the number and size of lipid droplets, and decreased intracellular TG content. Front Pharmacol. 2022 Jan 11;12:826628
RAW264.7 cells 6.25-50 μM 24 h To investigate the anti-inflammatory effects of Aurantio-obtusin on LPS-induced RAW264.7 cells. Results showed that Aurantio-obtusin significantly inhibited the production of NO, PGE2, and reduced the protein expression of COX-2, TNF-α, and IL-6. Molecules. 2018 Nov 27;23(12):3093
Human renal glomerular endothelial cells (HRGECs) 50, 100, 200 µM 48 h To assess the cytotoxic effects of AO on HRGECs. AO caused decreased cell viability, increased LDH leakage, increased secretion of inflammatory cytokines (IL-6, TNF-α, TGF-β1, MCP-1), and decreased ZO-1 expression. Nutrients. 2022 Nov 2;14(21):4615

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice HFHS diet-induced obese mouse model Oral gavage 10 mg/kg Once daily for 4 weeks AO significantly increased the weight of BAT and accelerated energy expenditure to protect the weight increase in the obese mice. Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840
C57BL/6J mice High-fat diet and glucose-fructose water (HFSW)-induced NAFLD mouse model Oral gavage 5, 10, 15 mg/kg Once daily for 4 weeks AO significantly alleviated HFSW-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC content, and improved liver histology. Front Pharmacol. 2022 Jan 11;12:826628
Sprague-Dawley (SD) rats Hepatotoxicity model Oral 4, 40, and 200 mg/kg Once daily for 28 days To study the hepatotoxic effects of Aurantio-obtusin in rats and identify potential biomarkers in urine. Results showed that 23 metabolites were identified as potential biomarkers, with 10 up-regulated and 13 down-regulated. Front Pharmacol. 2020 Aug 12;11:1237
C57BL/6J mice HFHS diet-induced obesity model Oral 10 mg/kg Once daily for 4 weeks To investigate the effect of AO on BAT function and hepatic inflammation in obese mice, AO improved mitochondrial function in BAT and reduced hepatic inflammation. Chin Med. 2025 Mar 25;20(1):41

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.03mL

0.61mL

0.30mL

15.14mL

3.03mL

1.51mL

30.28mL

6.06mL

3.03mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories